Price Chart
Login Required
This premium feature is reserved for our registered users. Join our community to unlock full technical capabilities.
This premium feature is reserved for our registered users. Join our community to unlock full technical capabilities.
All figures are in percentages unless otherwise specified
Intimation of 39th Annual General Meeting of Aurobindo Pharma Limited to be held on August 27, 2026.
Intimation of schedule of Earnings Call to be held on August 6, 2026 at 8:30 AM (IST) on Unaudited Financial Results of the Company for the first quarter ended June 30, 2026.
Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve Intimation of Board Meeting to be held on August 5, 2026 to consider the Standalone & Consolidated Unaudited Financial Results of the Company for the first quarter ended June 30, 2026.
Intimation of acquisition of majority ownership control in A1 Biochem Labs (India) Private Limited and A1 Biochem Labs LLC, USA.
Intimation of receipt of ANVISA approval for Biosimilar manufacturing facility of Curateq Biologics Private Limited, a wholly owned subsidiary of the Company.
Submission of certificate under regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended June 30, 2026.
Intimation of completion of transfer of Company''s domestic branded generic pharmaceutical formulations products business to Auropharm Limited, a wholly owned subsidiary of the Company.
Intimation of completion of acquisition.
Intimation of completion of acquisition.
Intimation of closure of Trading Window
Intimation of closure of Trading Window
All figures are in days unless otherwise specified